Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

Altis Labs has unveiled Nota, a groundbreaking clinical information platform designed to expedite therapeutic research and development. By harnessing the power of AI, Nota can forecast patient outcomes based on imaging data, allowing sponsors to efficiently prioritize their most promising therapies. This innovative platform empowers researchers to effectively utilize clinical trial imaging data, gain access to predictive imaging biomarkers, and enhance R&D efforts on a larger scale. With Altis’ cloud-based software, which employs advanced deep learning techniques, biopharma companies can integrate detailed outcome predictions at the image, patient, and cohort levels, ultimately refining clinical trial design and boosting confidence in anticipating clinical endpoints. The insights generated by Nota have the potential to drastically shorten development timelines, reduce drug development expenses, and increase the chances of success across various therapeutic areas, paving the way for a new era in clinical research. As the demand for efficient drug development continues to rise, Nota stands out as a vital tool for the biopharmaceutical industry.

Description

Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

No details available.

Integrations

No details available.

Pricing Details

No price information available.
Free Trial
Free Version

Pricing Details

No price information available.
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

Altis Labs

Founded

2019

Country

Canada

Website

www.altislabs.com/news/altis-labs-announces-launch-of-nota-a-clinical-information-platform-to-accelerate-therapeutic-r-d

Vendor Details

Company Name

Hillo

Country

France

Website

www.hillo.ai/

Product Features

Product Features

Alternatives

Alternatives

Ember Reviews

Ember

MetiStream
LaunchX Reviews

LaunchX

Nota AI
Altis Labs Nota Reviews

Altis Labs Nota

Altis Labs